Abiopharma

🔍 Rich Stuart (Director)

Company: TENAX THERAPEUTICS, INC. (TENX)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | shares_owned_after: 5,266.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | nature_of_ownership: By Stuart Rich 2022 Irrevocable Trust | shares_owned_after: 1,194.00 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | nature_of_ownership: By Andrea Rich 2021 Irrevocable Trust | shares_owned_after: 1,194.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | nature_of_ownership: By Stuart Rich Revocable Trust DTD 11/18/1996 | shares_owned_after: 5,000.00 | Footnotes: F3
• Acquired 250,000 shares of Stock Option (right to buy) at $13.3 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 250,000.00 | transaction_form_type: 4 | Footnotes: F4
• Holds 157 shares of Stock Option (right to buy) at $2848.0 per share (Derivative)
  Date: 2026-01-09 | Code: H | Expires: 2031-01-15 | shares_owned_after: 157.00 | Footnotes: F5
• Holds 63 shares of Stock Option (right to buy) at $992.0 per share (Derivative)
  Date: 2026-01-09 | Code: H | Expires: 2032-06-09 | shares_owned_after: 63.00 | Footnotes: F6
• Holds 119 shares of Stock Option (right to buy) at $3.549 per share (Derivative)
  Date: 2026-01-09 | Code: H | Expires: 2034-05-17 | shares_owned_after: 119.00 | Footnotes: F7
• Holds 500,000 shares of Stock Option (right to buy) at $5.94 per share (Derivative)
  Date: 2026-01-09 | Code: H | Expires: 2034-12-10 | Exercise: 2025-12-10 | shares_owned_after: 500,000.00
• Holds 625,000 shares of Stock Option (right to buy) at $5.89 per share (Derivative)
  Date: 2026-01-09 | Code: H | Expires: 2035-05-16 | shares_owned_after: 625,000.00 | Footnotes: F8

Footnotes:

• F1: The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F2: The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
• F3: The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
• F4: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
• F5: The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
• F6: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
• F7: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
• F8: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.